TapewireFind a company

person · Reporting owner

Fontenot Jason D.

Disclosed activity across 1 company

Tapewire entity
107941
SEC CIK
0001851761

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
SANGAMO THERAPEUTICS, INCSGMO · Entity 7038SVP, Chief Scientific OfficerNovember 25, 2023November 28, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

SANGAMO THERAPEUTICS, INC

Report date November 25, 2023 · Filed November 28, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect136,270 Reported balance After 2023-11-25 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2023-11-25 · Tax withholding · Disposed 1,030 · Balance 136,270

F1: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on November 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2023 of $0.3821/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.

F2: Includes: (a) 3,198 shares resulting from the November 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 21,141 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 7,344 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 42,750 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on November 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2023 of $0.3821/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.

F2: Includes: (a) 3,198 shares resulting from the November 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 21,141 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 7,344 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 42,750 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
November 25, 2023 Filed Nov 28, 2023 21:18 UTC SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 Tax withholdingCommon Stock 1,030 $0.38 $393.56
Disclosure

SEC source: 0001209191-23-056783 · doc4.xml · nonDerivative · entry 1

Fontenot Jason D. · CIK 0001851761 · SVP, Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,270

F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on November 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2023 of $0.3821/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.

F2 · balance_after: Includes: (a) 3,198 shares resulting from the November 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 21,141 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 7,344 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 42,750 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Read SEC document
August 25, 2023 Filed Aug 29, 2023 20:15 UTC SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 Tax withholdingCommon Stock 1,029 $0.77 $792.33
Disclosure

SEC source: 0001209191-23-047590 · doc4.xml · nonDerivative · entry 1

Fontenot Jason D. · CIK 0001851761 · SVP, Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,300

F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on August 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 25, 2023 of $0.77/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.

F2 · balance_after: Includes: (a) 3,199 shares resulting from the August 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 25,369 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 7,344 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 42,750 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Read SEC document
May 25, 2023 Filed May 30, 2023 20:42 UTC SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 Tax withholdingCommon Stock 1,029 $1.33 $1,368.57
Disclosure

SEC source: 0001209191-23-032907 · doc4.xml · nonDerivative · entry 1

Fontenot Jason D. · CIK 0001851761 · SVP, Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,329

F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on May 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2023 of $1.33/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.

F2 · balance_after: Includes: (a) 3,199 shares resulting from the May 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 29,597 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 7,344 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 42,750 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Read SEC document
February 25, 2023 Filed Mar 6, 2023 22:07 UTC SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 Tax withholdingCommon Stock 6,559 $2.66 $17,446.94
Disclosure

SEC source: 0001209191-23-016391 · doc4.xml · nonDerivative · entry 2

Fontenot Jason D. · CIK 0001851761 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,358

F2 · shares: Represents shares underlying the portions of RSU grants that vested on February 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2023 of $2.66/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.

F3 · balance_after: Includes: (a) 6,306 shares resulting from the February 25, 2023 final vesting installment of the Reporting Person's February 25, 2020 RSU grant, (b) 5,548 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2021 RSU grant and 7,344 shares subject to such RSU grant that will vest in one final installment on February 25, 2024, and (c) 8,530 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 33,825 shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Read SEC document
February 24, 2023 Filed Mar 6, 2023 22:07 UTC SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 GrantStock Option (Right to Buy) · Derivative 199,500 $0.00 Strike: $2.66 $0.00
Disclosure

SEC source: 0001209191-23-016391 · doc4.xml · derivative · entry 3

Fontenot Jason D. · CIK 0001851761 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 199,500

Underlying: Common Stock · 199,500 shares

Expires 2033-02-23

F4 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Read SEC document
February 24, 2023 Filed Mar 6, 2023 22:07 UTC SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 GrantCommon Stock 42,750 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016391 · doc4.xml · nonDerivative · entry 1

Fontenot Jason D. · CIK 0001851761 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,917

F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP.

Read SEC document
April 25, 2022 Filed Apr 27, 2022 21:09 UTC SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 Tax withholdingCommon Stock 826 $4.83 $3,989.58
Disclosure

SEC source: 0001209191-22-025811 · doc4.xml · nonDerivative · entry 1

Fontenot Jason D. · CIK 0001851761 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,167

F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on April 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on April 25, 2022 of $4.83/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP").

F2 · balance_after: Includes: (a) 2,508 shares resulting from the April 25, 2022 final annual vesting installment of the Reporting Person's April 25, 2019 RSU grant, (b) 8,335 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in one final annual installment on February 25, 2023, (c) 14,667 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in two remaining annual installments of 7,333 shares and 7,334 shares on February 25, 2023 and 2024, respectively, and (continued in footnote 3)

F3 · balance_after: (d) 45,100 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Read SEC document
February 25, 2022 Filed Mar 1, 2022 22:18 UTC SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 GrantStock Option (Right to Buy) · Derivative 121,770 $0.00 Strike: $5.90 $0.00
Disclosure

SEC source: 0001209191-22-014172 · doc4.xml · derivative · entry 3

Fontenot Jason D. · CIK 0001851761 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,770

Underlying: Common Stock · 121,770 shares

Expires 2032-02-24

F6 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Read SEC document
February 25, 2022 Filed Mar 1, 2022 22:18 UTC SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 GrantCommon Stock 45,100 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-014172 · doc4.xml · nonDerivative · entry 2

Fontenot Jason D. · CIK 0001851761 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,993

F5 · shares: Represents shares of common stock issuable upon settlement of an RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Read SEC document
February 25, 2022 Filed Mar 1, 2022 22:18 UTC SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 Tax withholdingCommon Stock 6,248 $5.90 $36,863.20
Disclosure

SEC source: 0001209191-22-014172 · doc4.xml · nonDerivative · entry 1

Fontenot Jason D. · CIK 0001851761 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,893

F1 · shares: Represents shares underlying the portions of restricted stock unit ("RSU") grants that vested on February 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on February 25, 2022 of $5.90/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP").

F2 · balance_after: Includes: (a) 7,565 shares resulting from the February 25, 2022 sole annual vesting installment of the Reporting Person's February 25, 2021 RSU grant, (b) 6,304 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2020 RSU grant and 8,335 shares subject to such RSU grant that will vest in one final annual installment on February 25, 2023, (c) 5,548 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2021 RSU grant and 14,667 shares subject to such RSU grant that will vest in two remaining annual installments of 7,333 shares and 7,334 shares on February 25, 2023 and 2024, respectively, and (see footnote 3)

F3 · balance_after: (d) 3,334 shares subject to the Reporting Person's April 25, 2019 RSU grant that will vest in one final annual installment on April 25, 2022. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

F4 · balance_after: Includes 1,953 shares acquired on April 30, 2021 and 692 shares acquired on October 29, 2021 under the Issuer's 2010 Employee Stock Purchase Plan.

Read SEC document
April 25, 2021 Filed Apr 28, 2021 00:49 UTC SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 Tax withholdingCommon Stock 811 $11.71 $9,496.81
Disclosure

SEC source: 0001209191-21-028745 · doc4.xml · nonDerivative · entry 1

Fontenot Jason D. · CIK 0001851761 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,496

F1 · shares: Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on April 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on April 23, 2021 of $11.71/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended").

F2 · balance_after: Includes: (a) 2,522 shares resulting from the April 25, 2021 vesting of the Reporting Person's April 25, 2019 RSU grant and 3,334 shares subject to such RSU grant that will vest on April 25, 2022; (b) 16,667 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in two remaining annual installments of 8,332 shares and 8,335 shares on February 25, 2022 and 2023 respectively; (c) 10,000 shares subject to a grant of RSUs to the Reporting Person on February 25, 2021 which will vest in full on the first anniversary of the grant date; and (continued in footnote 3)

F3 · balance_after: (d) 22,000 shares subject to a grant of RSUs to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.